Table 3.
Most important reported case series to date in which chemoradiotherapy was the primary treatment
| Authors | Year of publication | Number of patients included | Initial schema of chemotherapy | Initial regimen of RT (Gy) | Follow-up (months), median (range) | Outcome | Disease-free survival, % |
|---|---|---|---|---|---|---|---|
| Clark et al.45 | 2008 | 7 | 5-FU/cisplatin (4) 5-FU/MMC (3) |
50.4-54 | 18 (5-31) | ANED (7) | 100 |
| Sturgeon et al.46 | 2017 | 14 | 5-FU/cisplatin (10) Capecitabin/cisplatin (4) |
38-58.8 | 54 (21.6-195.6) | ANED (11) LR (3) |
72 (5 years) |
| Loganadane et al.7 | 2016 | 23 | 5-FU/cisplatin (12) 5-FU/MMC (3) Capecitabine/MMC (4) Cisplatin weekly (2) None (1) |
45-65 | 85 (12-161) | ANED (18) LR (2) M (2) LR + M (1) |
81 (5 years) |
| Musio et al.5 | 2015 | 8 | 5-FU/MMC (6) Raltitrexed + oxaliplatin (2) |
45-76.5 | 41.75 (1-164) | ANED (7) LR (1) |
87.5 |
| Nahas et al.18 | 2007 | 9 | 5-FU/MMC (6) 5-FU/cisplatin (3) |
50.4 | 31.2 (6-192) | ANED (9) | 100 |
| Péron et al.40 | 2015 | 10 | 5-FU/MMC (4) 5-FU/cisplatin (5) Capecitabine (1) |
45-62 | 42 (6-133) | ANED (8) LR (2) |
80 |
5-FU, 5-fluorouracil; ANED, alive with no evidence of disease; LR, local recurrence; LR + M, both local recurrence and metastasis; M, metastasis; MMC, mitomycin C; RT, radiotherapy.